Related Experiment Video

Updated: May 27, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma

Chieko Kudo1, Hiroyuki Yamakoshi, Atsuko Sato

  • 1Department of Clinical Oncology, Faculty of Medicine, Akita University, Hondo1-1-1, Akita, Japan.

Anticancer Research
|November 24, 2011
PubMed
Abstract

Insights

New curcumin analogs, GO-Y030 and GO-Y078, show enhanced potency in suppressing multiple myeloma cell growth and targeting key signaling pathways like NF-κB and PI3K/AKT.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Multiple myeloma is an incurable blood cancer with complex signaling pathways contributing to treatment failure.
  • Existing molecular-targeted agents show limited efficacy due to intricate molecular mechanisms.
  • Curcumin shows potential but is limited by poor bioavailability.

Purpose of the Study:

  • To synthesize and evaluate novel curcumin analogs (GO-Y030 and GO-Y078) for enhanced anti-myeloma activity.
  • To assess the targeted inhibition of key signaling pathways implicated in multiple myeloma.
  • To investigate the potential of these analogs as therapeutic candidates.

Main Methods:

  • Synthesis of novel curcumin analogs GO-Y030 and GO-Y078.
  • Analysis of growth-suppressive effects on multiple myeloma cells.
  • Evaluation of molecular targeting of NF-κB, PI3K/AKT, JAK/STAT3, and IRF4 pathways.
  • Assessment of inhibition of interleukin-6 (IL-6) production.

Main Results:

  • GO-Y030 and GO-Y078 demonstrated 7–12 fold greater growth suppression of myeloma cells compared to curcumin.
  • Analogs showed 6–15 fold stronger inhibition of NF-κB, PI3K/AKT, JAK/STAT3, and IRF4 pathways.
  • GO-Y78 exhibited 14-fold more potent inhibition of IL-6 production.

Conclusions:

  • GO-Y030 and GO-Y078 represent promising therapeutic candidates for multiple myeloma.
  • Enhanced potency and targeted pathway inhibition suggest clinical potential.
  • These analogs offer improved efficacy over curcumin for treating multiple myeloma.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...